Download FREE Sample
Table of Contents
- Research Methodology
1.1. Secondary Research
1.2. Primary Research
1.3. Market Estimation
1.4. Market Forecasting - Executive Summary
- Market Overview
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunities
3.1.4. Market Trend
3.2. Industry Speaks
3.3. Technology Trends - COVID-19 Impact on Companion Diagnostics Market
- Reimbursement Scenario: Snapshot
- Global Companion Diagnostics Market- Size & Forecast (2026-2031), By Technology
6.1. Polymerase Chain Reaction
6.2. Next-generation Sequencing
6.3. In Situ Hybridization
6.4. Immunohistochemistry
6.5. Other Technologies - Global Companion Diagnostics Market- Size & Forecast (2026-2031), By Indication
7.1. Oncology
7.2. Neurological Disorders
7.3. Cardiovascular Diseases
7.4. Infectious Diseases
7.5. Other Indications - Global Companion Diagnostics Market- Size & Forecast (2026-2031), By Region
8.1. North America (U.S. & Canada)
8.2. Europe (UK, Germany, France, Italy, Spain, Rest of Europe)
8.3. Asia Pacific (China, India, Japan, Rest of Asia Pacific)
8.4. Rest of the World (Latin America, Middle East & Africa) - Competitive Landscape
9.1. Key Players and their Competitive Positioning
9.1.1. Market Share Analysis (2026)
9.1.2. Segment-wise Player Mapping
9.2. Key Strategies Assessment, By Player (2026-2031)
9.2.1. New Product & Service Launches
9.2.2. Partnerships, Agreements, & Collaborations
9.2.3. Mergers & Acquisitions
9.2.4. Geographic Expansion - Key Companies Scanned (Indicative List)
10.1. Thermo Fisher Scientific Inc.
10.2. Illumina Inc.
10.3. Bayer AG
10.4. F. Hoffmann-La Roche AG
10.5. Siemens Healthineers AG
10.6. Danaher Corporation
10.7. Invitae
10.8. Aqilent Technologies, Inc
10.9. Almac Diagnostics
10.10. Qiagen Inc.
10.11. Foundation Medicine, Inc.
10.12. Abbott Laboratories
